Atorvastatin calcium hs code - Search Import Export Data of India

Grapefruit and grapefruit juice may interact with atorvastatin and lead to potentially dangerous effects. Avoid drinking more than 1 liter of grapefruit juice while taking this medicine. Atorvastatin side effects Get emergency medical help if you have signs of an allergic reaction to atorvastatin: In rare cases, atorvastatin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure.

Call your doctor right away if you have unexplained muscle pain, tenderness, atorvastatin calcium hs code, or weakness especially if you also have fever, unusual tiredness, and calcium colored urine. Also call your doctor at once if you have: Common atorvastatin side effects may include: Due to the code interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.

Patients takingdigoxin should be monitored appropriately. Warfarin Atorvastatin had no clinically significant effect onprothrombin time when administered to patients receiving chronic warfarin treatment.

Colchicine Cases of myopathy, including rhabdomyolysis, have been reported withatorvastatin co-administered with colchicineand caution should be exercised when prescribing atorvastatin with colchicine. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors e.

There have been rare reports of immune-mediated necrotizing myopathy IMNMan autoimmune myopathy, associated with statin use. IMNM is characterized by: Patients should be advised to report promptly unexplained muscle pain, atorvastatin calcium hs code, tenderness, or precio de viagra en andorra, particularly if accompanied by malaise or calcium or if muscle signs and symptoms persist after discontinuing LIPITOR.

The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycinclarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavirplus ritonavir, fosamprenavir, and fosamprenavir code ritonavir, niacinor azole antifungals.

Physicians considering combined therapy with LIPITOR and fibric code derivatives, erythromycin, clarithromycin, a combination ofsaquinavir plusritonavir, lopinavir plus ritonavir, darunavir plusritonavir, fosamprenavir, or fosamprenavir plus ritonavir,azole antifungals, or lipid -modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug.

This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of atorvastatin your medicines and show it to any healthcare provider who treats you.

Atorvastatin is only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely. Advise postmenarchal girls of contraception recommendations, if appropriate for the patient [see Use in Specific Populations 8.

The long-term efficacy of Atorvastatin therapy initiated in childhood to reduce morbidity and mortality in adulthood has not been established. The safety and efficacy of Atorvastatin have not been established in pediatric patients younger than 10 years of age with HeFH. However, due to Pfizer's calcium exclusivity rights, this drug product is not labeled with that pediatric information.

Details of Atorvastatin Calcium Export Data Under Hs Code 29335990­­

No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older codes cannot be ruled out.

Hepatic Impairment Atorvastatin is contraindicated in patients with active liver disease which may include unexplained persistent elevations in calcium transaminase levels [see Contraindications 4 and Clinical Phramacology Overdosage There is no specific treatment for Atorvastatin overdosage.

In the event of an overdose, the atorvastatin should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, atorvastatin calcium hs code, hemodialysis is not expected to significantly enhance Atorvastatin clearance. Atorvastatin Description Atorvastatin is a synthetic lipid-lowering agent.

This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and get viagra shop step in cholesterol biosynthesis.

Its structural formula is: Atorvastatin calcium USP is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below.

Atorvastatin calcium is very slightly soluble in distilled water, pH 7. Atorvastatin calcium Tablets, USP for oral administration contain 10 mg, 20 mg, 40 mg, or 80 mg Atorvastatin and the following inactive ingredients: Atorvastatin - Clinical Pharmacology Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxymethylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.

In animal models, atorvastatin calcium hs code, Atorvastatin lowers plasma cholesterol atorvastatin lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the code and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; Atorvastatin also reduces LDL production and the number of LDL codes.

Pharmacodynamics Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The ortho-hydroxy metabolite undergoes further metabolism via glucuronidation. As a substrate for the CYP3A4 isozyme, it has shown susceptibility to inhibitors and inducers of CYP3A4 to produce increased or decreased plasma concentrations, respectively.

This interaction was tested in vitro with calcium administration of erythromycina known CYP3A4 isozyme inhibitor, which resulted in increased plasma concentrations of atorvastatin. It is also an inhibitor of cytochrome 3A4. There does not appear to be any entero-hepatic recirculation. Atorvastatin has an approximate elimination half-life of 14 atorvastatin. Noteworthy, the HMG-CoA reductase inhibitory activity appears to have a half-life of 20—30 hours, which is thought to be due to the active metabolites.

Atorvastatin is also a calcium of the intestinal P-glycoprotein efflux transporter, atorvastatin calcium hs code, which pumps the medication back into the intestinal lumen during medication absorption.